Lineage Cell Therapeutics (LCTX) Enterprise Value (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Enterprise Value of -$63.9 million for Q1 2026, down 29.67% year-over-year from -$90.8 million in Q1 2025, and down 2.8% quarter-over-quarter from -$62.2 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Enterprise Value (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$63.9 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 29.67% year-over-year to -$63.9 million; the TTM figure through Mar 2026 stood at -$63.9 million (down 29.67% YoY), while the FY2025 annual figure was -$62.2 million, down 39.99% from the prior year.
- Enterprise Value for Q1 2026 stood at -$63.9 million, down from -$62.2 million in the prior quarter.
- The five-year high for Enterprise Value was -$31.4 million in Q4 2023, with the low at -$81.3 million in Q1 2022.
- The 5-year median for Enterprise Value is -$47.3 million (2023), against an average of -$51.0 million.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value jumped 47.06% in 2023, then tumbled 41.5% in 2024.
- Lineage Cell Therapeutics' Enterprise Value stood at -$59.3 million in 2022, then surged by 47.06% to -$31.4 million in 2023, then sank by 41.5% to -$44.4 million in 2024, then slumped by 39.99% to -$62.2 million in 2025, then slipped by 2.8% to -$63.9 million in 2026.
- Business Quant data shows LCTX's Enterprise Value at -$63.9 million in Q1 2026, -$62.2 million in Q4 2025, and -$33.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | -57.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -57.84 Mn |
| Mar 31, 2026 | -63.90 Mn |
| Dec 31, 2025 | -62.16 Mn |
| Sep 30, 2025 | -33.49 Mn |
| Jun 30, 2025 | -43.56 Mn |
| Mar 31, 2025 | -49.28 Mn |
| Dec 31, 2024 | -44.40 Mn |
| Sep 30, 2024 | -34.10 Mn |
| Jun 30, 2024 | -39.92 Mn |
| Mar 31, 2024 | -45.03 Mn |
| Dec 31, 2023 | -31.38 Mn |
| Sep 30, 2023 | -42.79 Mn |
| Jun 30, 2023 | -47.33 Mn |
| Mar 31, 2023 | -48.25 Mn |
| Dec 31, 2022 | -59.28 Mn |
| Sep 30, 2022 | -67.75 Mn |
| Jun 30, 2022 | -73.38 Mn |
| Mar 31, 2022 | -81.27 Mn |
| Dec 31, 2021 | -59.68 Mn |
| Sep 30, 2021 | -66.23 Mn |